Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methoxy-α-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes

Xenobiotica

Volumn 33, Issue 10, 2003, Pages 989-998

  Springer, D ^a   Staack, R F ^a   Paul, L D ^a   Kraemer, T ^a   Maurer, H H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' METHYLENEDIOXYPYRROLIDINOPROPIOPHENONE; 4' HYDROXYPYRROLIDINOPROPIOPHENONE; 4' METHOXY ALPHA PYRROLIDINOPROPIOPHENONE; BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; MEPHENYTOIN; PYRROLIDINE DERIVATIVE; QUINIDINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME KINETICS; HUMAN; HUMAN TISSUE; ION MONITORING; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; MASS SPECTROMETRY; PROTEIN EXPRESSION; RELATIVE ACTIVITY FACTOR;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; DNA, COMPLEMENTARY; HUMANS; KINETICS; LIVER; MASS SPECTROMETRY; METHYLATION; MICROSOMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MODELS, CHEMICAL; PROPIOPHENONES; PROTEIN ISOFORMS; PYRROLES; PYRROLIDINES; QUINIDINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS;

EID: 0242351749     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001602775     Document Type: Article

References (27)

1. BERTILSSON, L., 1995, Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics, 29, 192-209.
2. BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321-332.
3. BRYANT, S. G., GUERNSEY, B. G. and INGRIM, N. B., 1983, Review of bupropion. Clinical Pharmacology, 2, 525-537.
4. CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202.
5. CRESPI, C. L., 1995, Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. In B. Testa and U. A. Meyer (eds), Advances in Drug Research (London: Academic Press), pp. 179-235.
6. CRESPI, C. L. and MILLER, V. P., 1999, The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacology and Therapeutics, 84, 121-131.
7. CRESPI, C. L. and PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Advances in Pharmacology, 43, 171-188.
8. CREWE, H. K., LENNARD, M. S., TUCKER, G. T., WOODS, F. R. and HADDOCK, R. E., 1992, The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262-265.
9. EVANS, W. E. and MCLEOD, H. L., 2003, Pharmacogenomics - drug disposition, drug targets, and side effects. New England Journal of Medicine, 348, 538-549.
10. GLENNON, R. A., YOUSIF, M., NAIMAN, N. and KALIX, P., 1987, Methcathinone: a new and potent amphetamine-like agent. Pharmacology and Biochemical Behaviour, 26, 547-551.
11. GUENGERICH, F. P., PARIKH, A., YUN, C. H., KIM, D., NAKAMURA, K., NOTLEY, L. M. and GILLAM, E. M., 2000, What makes P450s work? Searches for answers with known and new P450s. Drug Metabolism and Reviews, 32, 267-281.
12. HUTZLER, J. M. and TRACY, T. S., 2002, Atypical kinetic profiles in drug metabolism reactions. Drug Metabolism and Disposition, 30, 355-362.
13. INOUYE, K., MIZOKAWA, T., SAITO, A., TONOMURA, B. and OHKAWA, H., 2000, Biphasic kinetic behavior of rat cytochrome P-4501A1-dependent monooxygenation in recombinant yeast microsomes. Biochimica et Biophysica Acta, 1481, 265-272.
14. KALIX, P. and GLENNON, R. A., 1986, Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochemical Pharmacology, 35, 3015-3019.
15. KORZEKWA, K. R., KRISHNAMACHARY, N., SHOU, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137-4147.
16. MARTINEZ, M., MERCADO, O., SANTAMARIA, A., GALVAN, S., VAZQUEZ, M., BUCIO, V., HALL, C., HERNANDEZ, R., HURTAZO, A., PEGO, E., RODRIGUEZ, F., SALVATIERRA, R., SOSA, A. and RIOS, C., 1998, The action of amfepramone on neurochemical and behavioral markers in rats. Proceedings of the Western Pharmacology Society, 41, 125-127.
17. MAURER, H. H., KRATZSCH, C., WEBER, A. A., PETERS, F. T. and KRAEMER, T., 2002, Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxy carbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry. Journal of Mass Spectrometry, 37, 687-692.
18. MILLER, G. P. and GUENGERICH, F. P., 2001, Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. Biochemistry, 40, 7262-7272.
19. NEWTON, D. J., WANG, R. W. and LU, A. Y., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
20. ODA, Y. and KHARASCH, E. D., 2001, Metabolism of levo-alpha- Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. Journal of Pharmacology and Experimental Therapeutics, 297, 410-422.
21. RODRIGUES, A. D., 1999, Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology, 57, 465-480.
22. ROESNER, P., JUNGE, T., FRITSCHI, G., KLEIN, B., THIELERT, K. and KOZLOWSKI, M., 1999, Neue synthetische Drogen: Piperazin-, Procyclidin-und alpha-Aminopropio-phenonderivate. Toxichem and Krimtech, 66, 81-90.
23. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
24. SMITH, D. A., ABEL, S. M., HYLAND, R. and JONES, B. C., 1998, Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica, 28, 1095-1128.
25. SPRINGER, D., FRITSCHI, G. and MAURER, H. H., 2003, Metabolism and toxicological detection of the new designer drug 4′-methoxy-alpha- pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. Journal of Chromatography B, 793, 331-342.
26. STORMER, E., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 2000, Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metabolism and Disposition, 28, 1168-1175.
27. VENKATAKRISHNAN, K., VON MOLTKE, L. L., COURT, M. H., HARMATZ, J. S., CRESPI, C. L. and GREENBLATT, D. J., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493-1504.